

HALOZYME THERAPEUTICS INC

Form 8-K

January 21, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 17, 2015

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-32335

(Commission
File Number)

88-0488686

(IRS Employer
Identification No.)

11388 Sorrento Valley Road, San Diego, California

(Address of principal executive offices)

92121

(Zip Code)

Registrant's telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On January 17, 2015, Dr. Jean-Pierre Bizzari was elected to the Board of Directors of Halozyme Therapeutics, Inc. He was elected to the class of directors with terms ending in 2015, and will stand for election to the Board by the Company's stockholders at the Company's 2015 annual meeting of stockholders. The Board of Directors has not yet determined the committee(s) of the Board on which Dr. Bizzari will serve. Dr. Bizzari will receive compensation for this services (currently consisting of cash retainers for Board and committee service and restricted stock awards) under our director compensation program applicable to all non-employee directors. The components of the non-employee director compensation program were described in our proxy statement for the 2014 Annual Meeting of Stockholders held on May 13, 2014. Under the director compensation program, on January 17, 2015, Dr. Bizzari was granted 3,437 shares of restricted stock, representing a pro rata portion of the value of a restricted stock award for the period of his service on the Board of Directors prior to the 2015 annual meeting of stockholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 21, 2015

HALOZYME THERAPEUTICS, INC.

By: /s/ David Ramsay

Name: David Ramsay

Title: Vice President and Chief Financial Officer